Insulin-like growth factor (IGF) levels in pre-treatment plasma identifying breast cancer: A case control study.

Pub Date : 2024-09-07 eCollection Date: 2024-01-01 DOI:10.22088/cjim.15.4.706

Sarvin Alizadeh Sadighi, Nematollah Rostami, Maryam Tohidi, Mahbobeh Mashayekhi

{"title":"Insulin-like growth factor (IGF) levels in pre-treatment plasma identifying breast cancer: A case control study.","authors":"Sarvin Alizadeh Sadighi, Nematollah Rostami, Maryam Tohidi, Mahbobeh Mashayekhi","doi":"10.22088/cjim.15.4.706","DOIUrl":null,"url":null,"abstract":"Background: Diabetes (primarily type 2) is linked to a higher risk of breast cancer. Insulin-like growth factor (IGF) is one of the most important factors that affects mitosis and thus inhibits apoptosis. The purpose of this study was to compare the pre-treatment insulin-like growth factor (IGF) levels in breast cancer against normal population.Methods: In this case-control study, 60 patients with breast cancer and 60 healthy controls were enrolled in 2017 and 2018 at Tehran's Shahid-Modarres Hospital. In this study, the blood sugar of the patients was examined before entering the study, and the age of the patients was also within the age limit of 18 to 70 years. They were studied to determine the relationship between insulin-like growth factor (ELISA method) and breast cancer.Results: Both groups have similar IGF-1 levels (Ctrl and Case) (P= 0.188). But, IGF-2 levels were significantly higher in breast cancer patients (373.4 vs. 317.3 ng/ml), (P=0.0001).Conclusion: According to our study, IGF-2 may serve as a prognostic biomarker and potential therapeutic target for breast cancer. However, further investigation is needed to validate this claim.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444118/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22088/cjim.15.4.706","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Diabetes (primarily type 2) is linked to a higher risk of breast cancer. Insulin-like growth factor (IGF) is one of the most important factors that affects mitosis and thus inhibits apoptosis. The purpose of this study was to compare the pre-treatment insulin-like growth factor (IGF) levels in breast cancer against normal population.

Methods: In this case-control study, 60 patients with breast cancer and 60 healthy controls were enrolled in 2017 and 2018 at Tehran's Shahid-Modarres Hospital. In this study, the blood sugar of the patients was examined before entering the study, and the age of the patients was also within the age limit of 18 to 70 years. They were studied to determine the relationship between insulin-like growth factor (ELISA method) and breast cancer.

Results: Both groups have similar IGF-1 levels (Ctrl and Case) (P= 0.188). But, IGF-2 levels were significantly higher in breast cancer patients (373.4 vs. 317.3 ng/ml), (P=0.0001).

Conclusion: According to our study, IGF-2 may serve as a prognostic biomarker and potential therapeutic target for breast cancer. However, further investigation is needed to validate this claim.

查看原文

乳腺癌治疗前血浆中的胰岛素样生长因子（IGF）水平：病例对照研究。

背景：糖尿病（主要是 2 型糖尿病）与罹患乳腺癌的风险较高有关。胰岛素样生长因子（IGF）是影响有丝分裂从而抑制细胞凋亡的最重要因素之一。本研究的目的是比较乳腺癌患者与正常人群治疗前的胰岛素样生长因子（IGF）水平：在这项病例对照研究中，德黑兰 Shahid-Modarres 医院于 2017 年和 2018 年招募了 60 名乳腺癌患者和 60 名健康对照者。在这项研究中，患者在进入研究前接受了血糖检查，年龄也在 18 至 70 岁的范围内。研究的目的是确定胰岛素样生长因子（ELISA 法）与乳腺癌之间的关系：两组患者的 IGF-1 水平相似（对照组和病例组）（P= 0.188）。但乳腺癌患者的 IGF-2 水平明显更高（373.4 vs. 317.3 ng/ml），（P=0.0001）：根据我们的研究，IGF-2 可作为乳腺癌的预后生物标志物和潜在治疗靶点。然而，要验证这一说法还需要进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文